IP Library Granted Patent US 11,690,969
Granted Patent B2
US 11,690,969 · App. 16/986,692 · Granted Jul 4, 2023

Delivery of gases to the nasal airway

Inventors: Per Gisle Djupesland (Oslo, NO); Roderick Peter Hafner (Wiltshire, GB)
Assignee: OptiNose Inc.
A61M16/0672A61M15/0003A61M15/0028A61M15/0065A61M15/0098A61M15/08A61M16/0003A61M16/0057A61M16/101A61M16/122A61M16/142A61M16/22A61M15/025A61M16/0808A61M2016/003A61M2016/0021A61M2016/0027A61M2016/0042A61M2202/025A61M2202/0208A61M2202/0225A61M2202/0266A61M2202/0275A61M2202/064A61M2205/3334A61M2210/0625
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,690,969
App. No.
16/986,692
Granted
Jul 4, 2023
Kind
B2
Abstract

A delivery device for and a method of delivering gases to the nasal airway, in particular therapeutic gases and gases in combination with active substances, either as powders or liquids, for enhanced uptake of the active substances.

Claims (34)

1. A pharmaceutical delivery device for delivering a substance and a gas to a nasal airway of a subject, comprising:

a nosepiece configured to fit to one nostril of the subject in use;

a mouthpiece fluidly connected to the nosepiece and configured to fit to an oral cavity of the subject in use, through which the subject in use exhales creating a flow of exhalation breath;

a substance supply unit fluidly connected to the nosepiece and configured to provide the substance into the flow of exhalation breath for delivery to the nasal airway of the subject; and

a gas generation unit fluidly connected to the nosepiece and configured to provide the gas into the flow of exhalation breath for delivery to the nasal airway of the subject, wherein the gas generation unit includes an air-permeable container, containing a powder.

2. The delivery device of claim 1 , wherein the powder, when exposed to the flow of exhalation breath, reacts to generate the gas.

3. The delivery device of claim 2 , wherein the powder is configured to react to moisture in the flow of exhalation breath.

4. The delivery device of claim 2 , wherein the powder includes a mixture of a carbonate or a bicarbonate salt and an acid.

5. The delivery device of claim 4 , wherein the powder includes a mixture of sodium bicarbonate and an acid.

6. The delivery device of claim 4 , wherein the acid is citric acid.

7. The delivery device of claim 4 , wherein the powder includes a mixture of sodium bicarbonate and citric acid.

8. The delivery device of claim 2 , wherein the gas is carbon dioxide.

9. The delivery device of claim 1 , wherein the gas is carbon dioxide.

10. The delivery device of claim 1 , wherein the container is replaceable.

11. The delivery device of claim 1 , wherein the container is a sachet.

12. The delivery device of claim 1 , wherein exhalation by the subject causes closure of an oropharyngeal velum of the subject.

13. The delivery device of claim 12 , wherein closure of the oropharyngeal velum prevents inhalation of the gas by the subject.

14. The delivery device of claim 1 , wherein the substance supply unit is configured to deliver an aerosol spray.

15. The delivery device of claim 1 , wherein the substance is a powder.

16. The delivery device of claim 1 , wherein the substance is a liquid.

17. A pharmaceutical delivery device for delivering a substance to a nasal airway of a subject, comprising:

a nosepiece configured to fit to one nostril of the subject in use;

a mouthpiece fluidly connected to the nosepiece and configured to fit to an oral cavity of the subject in use, through which the subject in use exhales creating a flow of exhalation breath;

a substance supply unit fluidly connected to the nosepiece and configured to provide the substance into the flow of exhalation breath for delivery to the nasal airway of the subject; and

a gas generation unit fluidly connected to the nosepiece and configured to generate carbon dioxide gas and provide the carbon dioxide gas into the flow of exhalation breath for delivery to the nasal airway of the subject, the gas generation unit including an air-permeable container, which contains a powder configured to react with, to the flow of exhalation breath to generate the carbon dioxide gas.

18. The delivery device of claim 17 , wherein the substance is a powder.

19. The delivery device of claim 17 , wherein the substance is a liquid.

20. The delivery device of claim 17 , wherein the powder is configured to react to moisture in the flow of exhalation breath.

21. The delivery device of claim 17 , wherein the powder includes a mixture of sodium bicarbonate and citric acid.

22. A pharmaceutical delivery device for delivering a substance and a gas to a nasal airway of a subject, comprising:

a nosepiece configured to fit to one nostril of the subject in use;

a mouthpiece fluidly connected to the nosepiece and configured to fit to an oral cavity of the subject in use, through which the subject in use exhales creating a flow of exhalation breath;

a substance supply unit fluidly connected to the nosepiece and configured to provide the substance into the flow of exhalation breath for delivery to the nasal airway of the subject; and

a gas generation unit fluidly connected to the nosepiece and configured to provide the gas into the flow of exhalation breath for delivery to the nasal airway of the subject, wherein the gas generation unit includes an air-permeable container.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71337/0132 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: OPTINOSE, INC.
Reel/Frame 075101/0804 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: OPTINOSE, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0018 →
SECURITY INTEREST Recorded May 22, 2025
From: OPTINOSE, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071337/0132 →
CHANGE OF ADDRESS Recorded Jan 2, 2025
From: OPTINOSE, INC.
To: OPTINOSE, INC.
Reel/Frame 069811/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: OPTINOSE AS
To: OPTINOSE INC
Reel/Frame 061546/0424 →
Priority Claims (1)
GB 0614811 · Jul 25, 2006 · national
Continuity (4)
Continuation 15869284 · Jan 12, 2018
Continuation 14560053 · Dec 4, 2014
Continuation 12375115
Related Publication 20210085907A1 · Mar 25, 2021